{
"id":"mk19_a_id_q029",
"number":29,
"bookId":"id",
"correctAnswer":"C",
"title":"Question 29",
"stimulus":[
{
"type":"p",
"hlId":"4dbc0a",
"children":[
"A 24-year-old woman is evaluated for HIV pre-exposure prophylaxis. She shares needles and other equipment for injection drug use. She has one sexual partner who is HIV negative; she uses condoms regularly."
]
},
{
"type":"p",
"hlId":"2dc718",
"children":[
"Vital signs and physical examination are normal."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"9d5fe2",
"children":[
"Laboratory studies: "
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"d6bb19",
"class":"cell text l",
"children":[
"Fourth-generation HIV-1/2 antigen/antibody combination assay"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"3a242b",
"class":"cell text l",
"children":[
"Hepatitis B surface antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"328929",
"class":"cell text l",
"children":[
"Positive"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"2ff2e8",
"class":"cell text l",
"children":[
"Hepatitis B surface antigen"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"74fe78",
"class":"cell text l",
"children":[
"Hepatitis C antibody"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"ffb935",
"class":"cell text l",
"children":[
"Negative"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"75f8a0",
"children":[
"A urine pregnancy test is negative."
]
},
{
"type":"p",
"hlId":"90a283",
"children":[
"The patient is counseled regarding consistent condom use and use of clean needles and equipment. She is referred to substance abuse treatment."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1e31fb",
"children":[
"Which of the following is the most appropriate additional management?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Tenofovir alafenamide, emtricitabine, and darunavir"
}
},
{
"letter":"B",
"text":{
"__html":"Tenofovir alafenamide or tenofovir disoproxil fumarate"
}
},
{
"letter":"C",
"text":{
"__html":"Tenofovir disoproxil fumarate and emtricitabine"
}
},
{
"letter":"D",
"text":{
"__html":"No additional management"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"7e1140",
"hvc":true,
"children":[
"Tenofovir disoproxil fumarate and emtricitabine, taken once daily, is the preferred regimen for women at high risk for HIV infection who engage in receptive vaginal intercourse and for persons who inject drugs using shared equipment."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"8ed7ab",
"children":[
"The most appropriate additional management is to initiate HIV pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF) and emtricitabine (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). Persons at high risk of HIV acquisition who should be considered for PrEP include men who have sex with men; men and women with a serodiscordant sexual partner; inconsistent condom use with a partner whose HIV status is unknown or is at high risk; syphilis or gonorrhea infection within the previous 6 months; and persons who share drug injection equipment. This patient shares drug injection equipment and should be considered for PrEP with the two-drug combination of TDF and emtricitabine, taken once daily."
]
},
{
"type":"p",
"hlId":"af44cc",
"children":[
"Persons taking PrEP who test positive for HIV should have a third drug (either ritonavir-boosted darunavir or dolutegravir) added to the two-drug PrEP regimen pending results of HIV RNA and viral resistance testing (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). A three-drug regimen cannot be recommended for this patient who has no evidence of HIV infection."
]
},
{
"type":"p",
"hlId":"684e7e",
"children":[
"In 2019, once-daily tenofovir alafenamide (TAF) and emtricitabine was approved for HIV PrEP for men at high risk. The efficacy of TAF-emtricitabine for PrEP in women who engage in receptive vaginal sex and persons who inject drugs is unknown, so it is not recommended at this time. Additionally, tenofovir and emtricitabineâ€“based regimens have been shown to have higher efficacy than tenofovir alone for PrEP; neither TDF nor TAF monotherapy is recommended for PrEP (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
")."
]
},
{
"type":"p",
"hlId":"ae66dc",
"children":[
"PrEP has been associated with a reduction in HIV transmission in groups of persons at high HIV risk, including persons who inject drugs. PrEP, along with access to clean needles and equipment and referral to substance abuse treatment, is indicated in this patient rather than no additional management (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
")."
]
}
],
"relatedSection":"mk19_a_id_s18_1",
"objective":{
"__html":"Prevent HIV infection in a person who injects drugs."
},
"references":[
[
"Owens DK, Davidson KW, Krist AH, et al; US Preventive Services Task Force. Preexposure prophylaxis for the prevention of HIV infection: US preventive services task force recommendation statement. JAMA. 2019;321:2203-2213. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31184747",
"target":"_blank"
},
"children":[
"PMID: 31184747"
]
},
" doi:10.1001/jama.2019.6390"
]
],
"hospitalist":false,
"hvc":true,
"peerComparison":{
"A":7,
"B":9,
"C":47,
"D":37,
"E":0
},
"hlIds":[
"4dbc0a",
"2dc718",
"9d5fe2",
"d6bb19",
"ffb935",
"3a242b",
"328929",
"2ff2e8",
"ffb935",
"74fe78",
"ffb935",
"75f8a0",
"90a283",
"1e31fb",
"7e1140",
"8ed7ab",
"af44cc",
"684e7e",
"ae66dc"
]
}